June 20 (Reuters) - The World Health Organization (WHO)

on Thursday issued warnings on falsified semaglutides used in

diabetes and weight-loss drugs in light of three falsified

batches of products detected in Brazil, the UK and the United

States.

Semaglutide is the active ingredient used in Novo Nordisk's

diabetes drug Ozempic and weight-loss treatment

Wegovy.

(Reporting by Kanjyik Ghosh; Editing by Devika Syamnath)